Donald L. Hagan LLC Takes $927,000 Position in Bristol Myers Squibb Company $BMY

Donald L. Hagan LLC purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 20,550 shares of the biopharmaceutical company’s stock, valued at approximately $927,000.

Several other institutional investors have also added to or reduced their stakes in BMY. Brighton Jones LLC raised its holdings in shares of Bristol Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after buying an additional 4,935 shares in the last quarter. Jump Financial LLC acquired a new position in Bristol Myers Squibb during the first quarter worth about $438,000. Ieq Capital LLC lifted its holdings in shares of Bristol Myers Squibb by 27.6% in the first quarter. Ieq Capital LLC now owns 172,523 shares of the biopharmaceutical company’s stock worth $10,522,000 after acquiring an additional 37,362 shares during the last quarter. CreativeOne Wealth LLC boosted its stake in shares of Bristol Myers Squibb by 6.4% in the 1st quarter. CreativeOne Wealth LLC now owns 32,748 shares of the biopharmaceutical company’s stock valued at $1,997,000 after purchasing an additional 1,969 shares in the last quarter. Finally, Transamerica Financial Advisors LLC grew its holdings in shares of Bristol Myers Squibb by 1.0% during the 1st quarter. Transamerica Financial Advisors LLC now owns 24,065 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 241 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $54.63 on Friday. The business has a 50-day moving average of $48.61 and a 200-day moving average of $47.33. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. The company has a market capitalization of $111.20 billion, a price-to-earnings ratio of 18.45, a price-to-earnings-growth ratio of 8.37 and a beta of 0.29. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The business had revenue of $12.22 billion for the quarter, compared to analysts’ expectations of $11.75 billion. During the same period in the prior year, the business posted $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Stockholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 4.6%. This is a boost from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 83.78%.

Wall Street Analyst Weigh In

BMY has been the subject of several research reports. BMO Capital Markets reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. Bank of America upgraded Bristol Myers Squibb from a “neutral” rating to a “buy” rating and increased their target price for the company from $52.00 to $61.00 in a research report on Monday, December 15th. Finally, HSBC restated a “hold” rating and set a $53.00 price target on shares of Bristol Myers Squibb in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $54.62.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.